Breast cancer registry study of treatment and outcomes
Part of Cancer, Skin clinical trials.
This is a registry study that collects real-world information about breast cancer care at the start of treatment. It may help researchers better understand which treatments work best for different groups of people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have early breast cancer (stage I–III) or advanced breast cancer (stage IV)
- You are starting your first major treatment for this diagnosis (before or right at the start of neoadjuvant/adjuvant for early disease, or first-line for advanced disease)
- Your sex can be male or female
- You must be able to give consent (or, for the retrospective part, have enough records available)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.